Abstract:
:Social dysfunction is often associated with depressive disorders and its evaluation is an important measure of treatment outcome. The aim of this study was to assess the effect of two treatments, venlafaxine and amitriptyline, on the social functioning of depressed patients. Twenty-eight outpatients, meeting criteria for recurrent or single major depressive episodes, took part in a double-blind, 8-week trial with amitriptyline or venlafaxine (maximum of 150 mg/day) and were assessed by the Self-Report Social Adjustment Scale (SAS-SR) before and at the end of treatment. The scale was also applied to a carefully selected non-psychiatric sample. Both drugs showed the same efficacy on a clinical scale, but venlafaxine improved social functioning more than amitriptyline as only venlafaxine-treated patients reached SAS-SR values estimated for normal subjects. This effect might be linked to the higher rate of side-effects observed with amitriptyline.
journal_name
Int Clin Psychopharmacoljournal_title
International clinical psychopharmacologyauthors
Gorenstein C,Andrade L,Moreno RA,Artes Rdoi
10.1097/00004850-200207000-00003subject
Has Abstractpub_date
2002-07-01 00:00:00pages
171-5issue
4eissn
0268-1315issn
1473-5857journal_volume
17pub_type
临床试验,杂志文章abstract::A new selective MAO-A-inhibitor (noclobemide) was used in a double-blind comparative study of 23 patients with severe unipolar or bipolar depressive disorder. Two different doses of medication were given for 4 weeks. Effectiveness was measured by improvements in the Hamilton Rating Scale for Depression, a self-rating ...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004850-198704000-00011
更新日期:1987-04-01 00:00:00
abstract::Systematic information about Latino clozapine users is still scarce. Our aim was to evaluate the risk of clozapine-associated neutropenia in a Chilean cohort using the last Food and Drug Administration's recommendations for clozapine monitoring. Findings should improve clinical practice and promote changes in clozapin...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0000000000000270
更新日期:2019-09-01 00:00:00
abstract::Sparse data exist regarding the risks and benefits of treating bipolar-II depression with antidepressants alone. On the basis of studies of bipolar-I patients, treatment guidelines suggest antidepressants should be augmented with mood stabilizers. Whether these recommendations apply to bipolar-II is unclear. A post-ho...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0b013e3280c28410
更新日期:2007-09-01 00:00:00
abstract::The effects of moclobemide, 450 mg/day, on sleep were investigated in 12 patients with major depression. The study was carried out over six weeks, divided into three periods: (1) treatment for one week with placebo and measurement to obtain baseline values; (2) treatment with moclobemide for four weeks; and (3) one we...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004850-199300730-00009
更新日期:1993-01-01 00:00:00
abstract::Characteristic response patterns are described for two antidepressant drugs and placebo in post-traumatic stress disorder. Early onset and steady improvement occurred on a global rating scale for both drugs and placebo in those who ultimately met responder criteria at the end of treatment. In certain cases, the magnit...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,评审
doi:10.1097/00004850-199711000-00001
更新日期:1997-11-01 00:00:00
abstract::There is uncertainty with regard to the appropriate use of metformin for the prevention and management of second-generation antipsychotic-induced weight gain and metabolic abnormalities. We aim to systematically review the primary literature and to provide recommendations with regard to the use of metformin in psychia...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/YIC.0b013e32834d0a5b
更新日期:2012-03-01 00:00:00
abstract::The effect of the antipsychotic drug trifluoperazine (TFP) on the in-vitro growth of 50 clinical isolates of Mycobacterium tuberculosis was tested. Of these isolates, 29 were susceptible to all five of the antitubercular drugs isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide, and 21 were resistant to o...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-199805000-00006
更新日期:1998-05-01 00:00:00
abstract::Fluvoxamine, a selective serotonin reuptake inhibitor, was investigated in a 6-week double-blind study among severely ill inpatients with DSM-III major depression. All but 1 patient also fulfilled criteria for melancholia. Following a 3-day placebo wash-out patients were randomly assigned to fluvoxamine, imipramine or...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004850-198907000-00006
更新日期:1989-07-01 00:00:00
abstract::Arrhythmias are a frequent and potentially fatal side effect of antipsychotic treatment. Strict ECG monitoring and clinical interviews are the standards used to prevent arrhythmias. A biologic predictive tool is missing. The identification of a genetic makeup at risk of antipsychotic-induced arrhythmias is the aim of ...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/YIC.0000000000000198
更新日期:2018-01-01 00:00:00
abstract::Major depressive disorder (MDD) is currently the second most common cause of disability worldwide. Current treatment of MDD with selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors is limited by efficacy and tolerability issues, highlighting the unmet need in the treatment of patien...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/YIC.0b013e3282f2b3cb
更新日期:2008-03-01 00:00:00
abstract::Lithium is widely used in the treatment of bipolar disorder. Here we describe the syndrome of irreversible lithium-effectuated neurotoxicity in a patient within therapeutic doses and levels, which persisted after discontinuation of Lithium. A 50-year-old gentleman with Bipolar disorder presented with symptoms of Mania...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0000000000000341
更新日期:2021-03-01 00:00:00
abstract::Clozapine is the only evidence-based antipsychotic for treatment-resistant schizophrenia. However, it has considerable side effects, limiting its usability and reducing patients' adherence. One of the most common and distressing side effects is hypersalivation, which can be debilitating, stigmatizing and potentially d...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/YIC.0000000000000251
更新日期:2019-03-01 00:00:00
abstract::This study is aimed at investigating the efficacy and tolerability of mirtazapine in a generalized social anxiety disorder. Sixty patients with generalized social anxiety disorder were randomly allocated to receive mirtazapine (30-45 mg/day) (n= 30) or placebo (n= 30) for 12 weeks in a double-blind study design. Prima...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/yic.0b013e32833a4d71
更新日期:2010-09-01 00:00:00
abstract::A priority in the treatment of depression is to obtain rapid improvement at an early stage. Since depressed patients, who are often convinced that nothing can be done for them, may well have difficulty in adhering to the therapeutic management plan, they can be both uncooperative and neglectful of treatment measures. ...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199707003-00005
更新日期:1997-07-01 00:00:00
abstract::The tendency of antipsychotics to produce extrapyramidal side-effects varies inversely with their antimuscarinic activity. This paper reviews the antipsychotic and antimuscarinic potency of these drugs and compares the total antimuscarinic activity in standard daily doses of antipsychotics, antiparkinson agents and an...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-198701000-00005
更新日期:1987-01-01 00:00:00
abstract::The chronic course of major depressive disorder (MDD) often impedes the ability of patients to achieve full remission. Return of full functioning is a critical goal of antidepressant pharmacotherapy as the presence of residual depressive symptoms is associated with an increased risk of relapse. Treatment guidelines re...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,meta分析
doi:10.1097/YIC.0000000000000121
更新日期:2016-05-01 00:00:00
abstract::The purpose of this study was to compare the efficacy and safety of risperidone and haloperidol in treatment-resistant chronic schizophrenic patients. Subjects (n = 78) who met DSM-III criteria for schizophrenia were randomly assigned to receive 6 mg/day of risperidone or 20 mg/day of haloperidol for 12 weeks. Clinica...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004850-200111000-00002
更新日期:2001-11-01 00:00:00
abstract::Social phobia and avoidant personality disorder were new diagnoses in the third version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) and were considerably changed in the revised third version (DSM-III-R). A high rate of comorbidity between these disorders was observed, which can be explained ...
journal_title:International clinical psychopharmacology
pub_type:
doi:
更新日期:1996-06-01 00:00:00
abstract::Long-term treatment with benzodiazepines (BZD) should be avoided in dementia patients because of an increased risk of adverse events. We evaluated how continuously dementia patients were prescribed BZD over 12 months. For this observational study, we used claims data from a large German public sickness fund for 2014 a...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0000000000000230
更新日期:2018-09-01 00:00:00
abstract::The aim of this study was to evaluate flexibly dosed brexpiprazole for early-episode schizophrenia through the assessment of efficacy, social functioning, and tolerability. This was an exploratory, 16-week, open-label, flexible-dose (1, 2, 3, or 4 mg/day; target dose 3 mg/day) study in outpatients with early-episode s...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/YIC.0000000000000140
更新日期:2016-11-01 00:00:00
abstract::We report that perospirone may have had positive effects on the obesity of three patients with schizophrenia and on the fasting blood sugar (FBS) and HbA1C of two of them who had type 2 diabetes mellitus. ...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-200401000-00008
更新日期:2004-01-01 00:00:00
abstract::Fourteen cases of depression resistant to multiple treatments were treated by lithium augmentation of fluoxetine. Tolerability of the treatment was poor. Lithium and fluoxetine may be a possible treatment for resistant depression but there is caution regarding tolerability and toxicity with the relatively high doses o...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-199400910-00005
更新日期:1994-04-01 00:00:00
abstract::Depressive symptoms are associated with poor outcomes, increased risk of relapse, and high suicide rates in patients with schizophrenia and schizoaffective disorder. This randomized, open-label, parallel-group, flexible-dose study (NCT00640562) assessed the efficacy of quetiapine extended release (XR) versus risperido...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1097/YIC.0000000000000017
更新日期:2014-05-01 00:00:00
abstract::In recent years the efficacy of new antipsychotics has been investigated through a number of randomized controlled trials. This paper considers some methodological flaws that affect these studies and proposes possible solutions. The final goal is the implementation of a new generation of trials with the aim of demonst...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-199903000-00012
更新日期:1999-03-01 00:00:00
abstract::A new short-acting thieno-diazepine compound, brotizolam, has been compared to nitrazepam in a double-blind trial. Following an initial 3-day control period with no treatment, insomniac patients were allocated to 2 weeks treatment with one or the other drug according to random selection. This was then followed by a fu...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004850-198601000-00005
更新日期:1986-01-01 00:00:00
abstract::Predicting the outcome of treatment with neuroleptics and understanding the factors that contribute to variability in the response to these drugs have preoccupied researchers and clinicians since the class was developed. Clinicians need empirically based prospective criteria in order to choose a treatment strategy tha...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199605002-00008
更新日期:1996-05-01 00:00:00
abstract::Since the discovery that clomipramine was effective in the treatment of obsessive-compulsive disorder (OCD), trials of several different medications for OCD have been published. The question of which agent, if any, is the medication of choice in OCD is of real clinical concern. Published clinical trials were collected...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,meta分析
doi:10.1097/00004850-199503000-00002
更新日期:1995-03-01 00:00:00
abstract::This analysis characterizes patients with schizophrenia or schizoaffective disorder treated with risperidone who met remission criteria. In a 50-week, open-label trial, stable patients received long-acting injectable risperidone every 2 weeks. Remission criteria included severity (absent-mild ratings on core symptoms ...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/01.yic.0000224791.06159.88
更新日期:2007-01-01 00:00:00
abstract::DEPRESS (Depression Research in European Society) is the first large pan-European survey of depression in the community. A total of 13359 of the 78463 adults who participated in screening interviews across six countries were identified as suffering from depression, a 6-month prevalence of 17%. Major depression account...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:
更新日期:1997-01-01 00:00:00
abstract::The objective of the present study was to evaluate the efficacy of mianserin and trazodone as antidepressants with serotonin 2 antagonist properties on negative symptoms and tardive dyskinesia in elderly patients with chronic schizophrenia. In this double-blind, placebo-controlled study the dose of each drug was incre...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00004850-199707000-00003
更新日期:1997-07-01 00:00:00